Table 1.

Main characteristics of included cost-effectiveness analyses

Author, Year	Study Design	Region	Perspective	Intervention Type
Cherry et al., 2012[22]	• Model-based study	• U.K.	• Healthcare system	• Blood transfusion
Spackman et al., 2014[23]	• Model-based study	• U.K.	• Healthcare system	• Blood transfusion
Arnold et al., 2015[24]	• Observational study	• U.S.	• Healthcare institution or hospital	• Transplantation
Cunningham-Myrie et al., 2015[25]	• Observational study	• Jamaica	• Healthcare system	• Pharmaceuticals
Bradt et al., 2020[26]	• Model-based study	• U.S.	• Healthcare system • Modified societal	• Pharmaceuticals
Salcedo et al., 2021[27]	• Model-based study	• U.S.	• Healthcare system	• Hypothetical cell or genetic therapy
Castilla-Rodríguez et al., 2016[28]	• Model-based study	• Spain	• Healthcare system	• Screening
Kuznik et al., 2016[29]	• Model-based study	• Sub-Saharan Africa	• Healthcare system	• Screening
McGann et al. 2015[30]	• Model-based study	• Angola	• N/A	• Screening
Bryan et al., 2011[31]	• Model-based study	• U.K.	• Healthcare system	• Screening
Kacker et al., 2014 (a)[32]	• Model-based study	• U.S.	• Hospital	• Intervention for treatment complications
Kacker et al., 2014 (b)[33]	• Model-based study	• U.S.	• Hospital	• Intervention for treatment complications
McLeod et al., 2009[34]	• Model-based study	• U.K.	• Healthcare system	• Intervention for treatment complications

N/A = not available; U.K. = United Kingdoms; U.S. = United States